QSAR and 3D QSAR in drug design part 2: Applications and problems

Drug Discovery Today

Volumn 2, Issue 12, 1997, Pages 538-546

  Kubinyi, Hugo ^a  

^a BASF SE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; CARDIOVASCULAR AGENT; HYDROLASE; LIGASE; OXIDOREDUCTASE;

ANTIHYPERTENSIVE ACTIVITY; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLOOD PLACENTA BARRIER; CALCULATION; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG STRUCTURE; ENZYME INHIBITION; LIGAND BINDING; LIPOPHILICITY; METHODOLOGY; RECEPTOR BINDING; REVIEW; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 0030828787     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(97)01084-2     Document Type: Review

References (42)

1. Kubinyi, H. (1997) Drug Discovery Today 2, 457-467 (Part 1).
2. Ramsden, C.A., ed. (1990) Quantitative Drug Design (Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds) (Vol. 4) (Hansch. C., Sammes, P.G. and Taylor, J.B., eds), Pergamon Press.
3. Kubinyi, H. (1993) QSAR: Hansch Analysis and Related Approaches, VCH.
4. Hansch, C. and Leo, A. (1995) Exploring QSAR. Fundamentals and Applications in Chemistry and Biology, American Chemical Society.
5. Kubinyi, H. (1995) in Burger's Medicinal Chemistry (Vol. 1, 5th edn) (Wolff, M.E., ed.), pp. 497-571, John Wiley & Sons.
6. Kubinyi, H., ed. (1993) 3D QSAR in Drug Design. Theory, Methods and Applications, ESCOM Science Publishers.
7. Green S.M., Marshall G.R. Trends Pharmacol. Sci. 16:1995;285-291.
8. Kim, K.H. (1995) in Molecular Similarity in Drug Design (Dean, P.M., ed.), pp. 291-331, Chapman & Hall.
9. Martin, Y.C. and Lin, C.T. (1996) in The Practice of Medicinal Chemistry (Wermuth, C.G., ed.), pp. 459-483, Academic Press.
10. Blankley, C.J. (1996) in Structure-Property Correlations in Drug Research (van de Waterbeemd, H., ed.), pp. 111-177, Academic Press.
11. Martin, Y.C., Kim, K-H. and Lin, C.T. (1996) in Advances in Quantitative Structure Property Relationships (Vol. 1) (Charton, M., ed.), pp. 1-52, JAI Press, Greenwich, CT, USA.
12. Kubinyi, H., Folkers, G. and Martin, Y.C., eds (1997) 3D QSAR in Drug Design. Volume II: Ligand-Protein Interactions and Molecular Similarity and Volume III: Recent Advances, Kluwer Academic Publishers.
13. van de Waterbeemd H., Kansy M. Chimia. 46:1992;299-303.
14. Pliska, V., Testa, B. and van de Waterbeemd, H., eds (1996) Lipophilicity in Drug Action and Toxicology, VCH.
15. Hansch C., Björkroth J.P., Leo A. J. Pharm. Sci. 76:1987;663-687.
16. Camenisch G., Folkers G., van de Waterbeemd H. Pharm. Acta Helv. 71:1996;309-327.
17. Navia M.A., Chaturvedi P.R. Drug Discovery Today. 1:1996;179-189.
18. Blaney J.M.et al. Chem. Rev. 84:1984;333-407.
19. Böhm, H-J., Klebe, G. and Kubinyi, H. (1996) Wirkstoffdesign, pp. 363-380 and 399-436, Spektrum Akademischer Verlag.
20. Unger S.H., Hansch C. J. Med. Chem. 16:1973;745-749.
21. Thibaut U.et al. Quant. Struct.-Act. Relatsh. 13:1994;1-3.
22. Böhm, H-J. and Klebe, G. (1996) Angew. Chem. 108, 2750-2778, Angew. Chem., Int.Eed. Engl. 35, 2588-2614.
23. Böhm, H-J. and Klebe, G. (1996) Angew. Chem. 108, 2750-2778, Angew. Chem., Int.Eed. Engl. 35, 2588-2614.
24. Meyer E.F. Perspect. Drug Des. Discovery. 3:1995;168-195.
25. Roques B.P.et al. Pharmacol. Rev. 45:1993;87-146.
26. Morgan B.P.et al. J. Am. Chem. Soc. 113:1991;297-307.
27. Xiang S.et al. Biochemistry. 34:1995;4516-4523.
28. Rogers D., Hopfinger A.J. J. Chem. Inf. Comput. Sci. 34:1994;854-866.
29. Kubinyi H. J. Chemomet. 10:1996;119-133.
30. van de Waterbeemd, H., ed. (1995) Chemometric Methods in Molecular Design, VCH.
31. van de Waterbeemd, H., ed. (1995) Advanced Computer-Assisted Techniques in Drug Discovery; VCH.
32. Baroni M.et al. Quant. Struct.-Act. Relatsh. 12:1992;9-20.
33. Topliss J.G., Costello R.J. J. Med. Chem. 15:1972;1066-1068.
34. Cramer, R.D., III et al. (1988) Quant. Struct.-Act. Relatsh. 7, 18-25, erratum (1988) 7, 91.
35. Cramer, R.D., III et al. (1988) Quant. Struct.-Act. Relatsh. 7, 18-25, erratum (1988) 7, 91.
36. Hansch C. Acc. Chem. Res. 26:1993;147-153.
37. Cramer R.D. III, Patterson D.E., Bunce J.D. J. Am. Chem. Soc. 110:1988;5959-5967.
38. th European Symposium on Quantitative Structure-Activity Relationships, Lausanne, 1996) (van de Waterbeemd, H., Testa, B. and Folkers, G., eds), pp. 7-28, Verlag Helvetica Chimica Acta and VCH.
39. Fujita, T. (1990) in Quantitative Drug Design (Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds) (Vol. 4) (Hansch, C., Sammes, P.G. and Taylor, J.B., eds), pp. 497-560, Pergamon Press.
40. Boyd, D.B. (1990), in Reviews in Computational Chemistry (Vol. 1) (Lipkowitz, K.B. and Boyd, D.B., eds), pp. 355-371, VCH.
41. Fujita, T. (1992) in QSAR in Design of Bioactive Compounds (Kuchar, M., ed.), pp. 3-22, Prous Science Publishers.
42. Fujita T. Quant. Struct.-Act. Relatsh. 16:1997;107-112.